BioStock talked to Steve Ross, co-founder of Psyros Diagnostics, which was acquired by Prolight Diagnostics in 2022. He and the other co-founders play a crucial role in steering the continued development of the point-of-care system Psyros. Together, as a team, they have previously navigated the full process of developing a POC system, from conceptualization to market, and completed a successful exit to Novartis in 2012.
Read the full article at: https://www.biostock.se/en/2024/02/prolight-diagnostics-cto-highlights-the-potential-of-the-psyros-system/
